Orchid Pharma has entered into a manufacturing sublicense agreement with Global Antibiotic Research & Development Partnership (GARDP) to manufacture Cefiderocol- an antibiotic to treat certain Gram-negative infections.
This agreement is a critical step in an ambitious project by Shionogi & Co. (Shionogi), GARDP, and the Clinton Health Access Initiative (CHAI) that aims to provide access to Cefiderocol in a number of predominantly low and middle-income countries.
Orchid Pharma, established as an export-oriented unit (EOU), is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1693.15 |
| Dr. Reddys Lab | 1221.25 |
| Cipla | 1230.75 |
| Zydus Lifesciences | 939.20 |
| Lupin | 2326.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: